These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31046917)

  • 1. Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis.
    Martínez-Doménech Á; García-Legaz-Martínez M; Magdaleno-Tapial J; Giácaman M; Hernández-Bel P; Pérez-Ferriols A
    Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab.
    Hlaca N; Zagar T; Kastelan M; Brajac I; Prpic-Massari L
    Clin Exp Dermatol; 2021 Dec; 46(8):1572-1573. PubMed ID: 34028847
    [No Abstract]   [Full Text] [Related]  

  • 3. Paradoxical Arthritis Due to Ixekizumab in a Patient With Plaque Psoriasis.
    Vidal D; Ros S; Reina D
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):255-256. PubMed ID: 29861037
    [No Abstract]   [Full Text] [Related]  

  • 4. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
    Puig L
    Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
    Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
    Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local injection of micro-dose guselkumab for palmoplantar pustulosis after partial failure of systemic ixekizumab treatment.
    Zhou C; Chen D; Diao Z; Wang Y; Hou Y; Yin Z
    Australas J Dermatol; 2024 May; 65(3):e75-e76. PubMed ID: 38439213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple paradoxical reactions during ixekizumab therapy.
    Pirro F; Caldarola G; De Simone C; Moretta G; Giovanardi G; Peris K
    Dermatol Ther; 2019 May; 32(3):e12852. PubMed ID: 30747476
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debut Of Inflammatory Bowel Disease Associated To Ixekizumab In Patient With Moderate, Difficult -To-Manage Psoriasis.
    Merino Gallego E; Gómez Torres K; Martínez Amate E
    Gastroenterol Hepatol; 2020 Dec; 43(10):622-623. PubMed ID: 32674878
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The successful treatment with ixekizumab in a multi-failure psoriasis patient.
    Azevedo A; Torres T
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
    Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
    Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
    Megna M; Cinelli E; Balato A; Gallo L; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e152-e153. PubMed ID: 31715054
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.